INTRODUCTION {#s1}
============

Thrombocytopenia-absent radius (TAR) syndrome (MIM\#274000) is a rare inherited disorder characterized by neonatal thrombocytopenia and bilateral radial aplasia with thumbs present. The arm and hand anomalies in TAR are distinctly different than Fanconi anemia in which thumbs are absent or malformed ([@MCS004564BROC7]; [@MCS004564BROC21]). Congenital heart disease has been reported in ∼10% of individuals with TAR and structural renal anomalies in ∼7% ([@MCS004564BROC5]; [@MCS004564BROC1]). Additionally, bloody diarrhea or enteritis associated with cow\'s milk intolerance has been reported in ∼20% of cases ([@MCS004564BROC22]; [@MCS004564BROC21]). The thrombocytopenia in infancy typically improves within the first 1--2 years of life, although platelet counts may not reach normal levels ([@MCS004564BROC12]). Notably, the degree of thrombocytopenia in TAR varies, and some patients have normal or near-normal platelet counts throughout life ([@MCS004564BROC12]).

TAR is caused by biallelic autosomal recessive inheritance of a deletion at Chromosome 1q21.1 from one healthy parent and a single-nucleotide polymorphism (SNP) in the 5′ untranslated region (UTR) (rs139428292 G \> A) or intron 1 (rs201779890 G \> C) of the RNA binding motif protein 8A gene (*RBM8A*) encoding the Y14 protein on the nondeleted 1q21.1 allele from the other parent ([@MCS004564BROC10]; [@MCS004564BROC9]; [@MCS004564BROC2]). Inheritance of two pathogenic variants in *RBM8A* has also been reported to cause TAR ([@MCS004564BROC2]). The combination of the 1q21.1 deletion and the 5′ UTR SNP (rs139428292) is associated with RBM8A haploinsufficiency and a classic TAR phenotype, including neonatal thrombocytopenia ([@MCS004564BROC2]; [@MCS004564BROC12]). In contrast, patients with the intron 1 SNP (rs201779890) and the 1q21.1 deletion were reported to have had normal or nearly normal platelet counts ([@MCS004564BROC12]).

Chromosome 1q21.1deletions and duplications are associated with phenotypes ranging from intellectual disability, autism, congenital heart defects, renal and urinary abnormalities, and dysmorphic faces in addition to TAR ([@MCS004564BROC17]). The minimally deleted region of 1q21.1 associated with TAR is ∼200 kilobases (kb) and not reported to overlap with deleted regions in other disorders. Mapping of 1q21.1--q21.2 has been challenging because of its highly repetitive nature, and the sequence was only considered "solved" in 2014 ([@MCS004564BROC16]).

In this study, we evaluated siblings with bony abnormalities and other clinical features consistent with TAR but without the typical TAR-associated thrombocytopenia of infancy. A series of genomic evaluations resulted in the fine mapping of the 1q21.1 deletion in these individuals and discovered a novel functional SNP (rs61746197) on 1q21.1 associated with their phenotypes.

RESULTS {#s2}
=======

Clinical Presentations {#s2a}
----------------------

The clinical features of the patients are shown in [Table 1](#MCS004564BROTB1){ref-type="table"} and [Figure 1](#MCS004564BROF1){ref-type="fig"}. The proband, NCI-107-1, had bilaterally absent radii, other bony abnormalities, and congenital heart disease but was not noted to have thrombocytopenia until about age 12 yr, despite having had several surgeries. TAR was not suspected in his older sister (NCI-107-2) until it was considered in the differential diagnosis for the proband. The sister\'s extremity abnormalities, congenital bilateral radial head dislocation, a slightly hypoplastic right radial head, and proximal ulnar hypoplasia were initially thought to be a result of in utero oligohydramnios. She had no history of thrombocytopenia. Both parents were evaluated and were healthy with no dysmorphology or medical problems. There was no other significant family history, and the family was of Caucasian ancestry.

![Skeletal features of study participants. (*A*--*C*) Proband, NCI-107-1. (*A*) Absent left radius and hypoplastic left ulna; (*B*) absent right radius and short right ulna; status post--multiple corrective surgeries for right thumb hypoplasia including tendon transfer and centralization; (*C*) normal right humerus. (*D*,*E*) Sister, NCI-107-2. (*D*) Wide left radius with mild hypoplasia and bony fusion of the proximal radial head to the distal humerus at the left elbow; (*E*) the right radius and ulna are normal; (*D*,*E*) both hands are normal with complete skeletal maturation.](MCS004564Bro_F1){#MCS004564BROF1}

###### 

Hematologic and nonhematological characteristics of study participants

  Participant, sex    Age at study   Hematology   Nonhematological features                
  ------------------- -------------- ------------ --------------------------- ------ ----- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NCI-107-1, male     14 yr          0.2          19,200                      10.8   222   Born at term with bilateral absent radii and hypoplastic ulnae, right thumb and right thenar eminence hypoplasia; bilateral proximal tibial deformities (Blount\'s disease); bilateral hip dysplasia; craniofacial dysmorphism with high prominent forehead and receding hairline, flat nasal bridge with bulbous tip, low-set ears, micrognathia, hypertelorism, and down-slanting eyes; atrial septal defect and cleft mitral valve. Height was 15th percentile for age.
  12                  5730           12.8         116                                      
  14                  5890           14.7         147                                      
  NCI-107-2, female   22 yr          Birth        11,000                      14     NR    Born preterm at 31-wk gestation with oligohydramnios and single umbilical artery. Flexion deformities of both elbows and bilateral radial head dislocation, hypoplastic left radius with bony fusion of radial head with distal humerus; duplicated collecting system in the right kidney; numerous small hemangiomas; hydrocephalus; craniofacial dysmorphism with high forehead and receding hairline, synophris, hypertelorism, high-arched palate, microsomia. No history of thrombocytopenia. Height was ninth percentile for age.
  3.8                 9100           13.6         172                                      
  13                  5100           14.2         169                                      
  22                  4560           13.7         183                                      

See also [Figure 1](#MCS004564BROF1){ref-type="fig"}.

(WBC) White blood cell count, (Hb) hemoglobin, (Plt) platelets, (L) liter, (NR) not reported.

Genomic Characterization {#s2b}
------------------------

Both siblings and one unaffected parent carry a deletion at 1q21.1 (Chr 1:145,601,946-148,597,425, hg38) identified by research and confirmed by clinical aCGH testing. Targeted sequencing of the deleted region identified the common alleles of the previously identified TAR-associated SNPs (rs139428292 and rs201779890) in all four family members and did not identify additional variants of interest. Whole-exome sequencing did not identify variants in genes associated with similar phenotypes such as *MECOM* ([@MCS004564BROC15]), *HOXA11* ([@MCS004564BROC20]), *TBX5* ([@MCS004564BROC14]), or Fanconi anemia ([@MCS004564BROC18]). There were three homozygous variants shared by both siblings, Chr 1:145515394 A \> G (rs61746197, hemizygous because of 1q21.1 deletion), Chr 6:130504476 C \> T, and Chr 12:52695897 G \> A (rs35018791) aligned to hg19 ([Table 2](#MCS004564BROTB2){ref-type="table"}). rs35018791 is a missense variant in keratin 86 and is in a highly polymorphic region of the genome with many pseudogenes. The Chr 6:130504476 C \> T variant has not been previously reported but is located in an intron of *SAMD3* (sterile α motif domain containing 3) and not bioinformatically predicted to be deleterious.

###### 

Coordinates by genome build of 1q21.1 deletion and SNPs of interest

                                 Chr   hg18 start      hg18 stop       hg19 start      hg19 stop       hg38 start    hg38 stop
  ------------------------------ ----- --------------- --------------- --------------- --------------- ------------- -------------
  Brother aCGH                   1     *144,003,055*   *144,967,596*   146,950,065     147,253,662     145,601,946   148,597,425
  Sister aCGH                    1     *144,003,055*   *144,967,596*   146,919,485     147,253,662     145,601,946   148,597,425
  rs61746197                     1     144,227,001     144,227,001     *145,919,695*   *145,919,695*   145,919,695   145,919,695
  RelA--p65                      1                                     *145,515,380*   *145,515,409*   145,919,688   145,919,698
  Sister whole-genome seq        1                                                                     145,370,001   146,190,000
  TAR common deleted region^a^   1     144,215,938     144,320,529     145,504,581     145,609,172     145,825,941   145,930,512
  *RBM8A*                        1     144,218,995     144,422,801     145,507,557     145,513,535     145,921,556   145,927,536
  rs139428292^b^                 1     Not in hg18     Not in hg18     145,927,447     145,927,447     145,927,447   145,927,447
  rs201779890^b^                 1     Not in hg18     Not in hg18     145,927,328     145,927,328     145,927,328   145,927,328

hg38 coordinates are based on alignments of patient whole-genome sequence data to the hg38 (GRCh38.p7) reference sequence. aCGH was performed with probes for hg18. Liftover of Chromosome 1q21.1 coordinates was performed with default settings of the UCSC genome browser liftover tool with the exception of the aCGH liftover from hg18 to hg38 in which there was limited alignment because of repetitive sequence. The RelA--p65 binding site, rs139428292, and rs201779890 were not present in hg18. *Italics* indicates build in which the region or variant was first identified. SNP locations in hg38 are based upon dbSNP build 151.

(Chr) Chromosome, (SNP) single-nucleotide polymorphism, (cCGH) array comparative genomic hybridization, (seq) sequencing, (TAR) thrombocytopenia-absent radii syndrome.

^a^Region reported by [@MCS004564BROC10].

^b^SNPs previously associated with TAR.

rs61746197 A \> G is in the 3′ UTR of *RBM8A* but was not located in the 1q21.1 deleted region in human genome build hg19. Using the UCSC Genome Browser liftover tool, we found that rs61746197A \> G is located in the deletion in build hg38. Whole-genome sequencing of NCI-107-2 with alignment to hg38 confirmed that rs61746197 A \> G is in the deleted region of 1q21.1 ([Table 2](#MCS004564BROTB2){ref-type="table"}). Sanger sequencing confirmed that both siblings carried only the variant (G) allele, and the parent without deleted 1q21.1 was heterozygous A/G at this location. The minor allele frequency (MAF) of rs61746197 A \> G in the gnomAD database is 0.5% (997/183,070). [Table 3](#MCS004564BROTB3){ref-type="table"} compares the MAF of this 3′ UTR *RBM8A* SNP with that of the 5′ UTR and intron 1 SNPs.

###### 

Frequency of TAR-associated SNPs in the literature, ClinVar, and gnomAD

  SNP                  SNP location in relation to *RBM8A*   Number of reported cases                                    Number of ClinVar submissions   Allele count/allele number, MAF in all of gnomAD
  -------------------- ------------------------------------- ----------------------------------------------------------- ------------------------------- --------------------------------------------------
  rs61746197 A \> G    3′ UTR                                2 (the siblings in this report)                             None                            997/183,070, 0.005446
  rs139428292 G \> A   5′ UTR                                24/38 cases reported and summarized by [@MCS004564BROC12]   9                               4831/269,236, 0.01794
  rs201779890 G \> C   Intron 1                              14/38 cases reported and summarized by [@MCS004564BROC12]   8                               1515/265,508, 0.005706

References: ClinVar ([@MCS004564BROC11]), <https://www.ncbi.nlm.nih.gov/clinvar/>; gnomAD ([@MCS004564BROC010]), <https://gnomad.broadinstitute.org>.

The rs61746197 Variant Allele Disrupts Transcription Factor Binding {#s2c}
-------------------------------------------------------------------

rs61746197 A \> G is a noncoding variant located 1861 base pairs 3′ of *RBM8A* and predicted to overlap with three transcripts of the *GNRHR2* pseudogene and the promoter of *PEX11B* ([Fig. 2](#MCS004564BROF2){ref-type="fig"}). We first evaluated whether rs61746197 A \> G was associated with changes in expression of nearby genes *LIX1L*, *PEX11B*, and/or *RBM8A* by performing qPCR of RNA from patient-derived primary fibroblast cultures and/or EBV-transformed lymphoblastoid cell lines. There were no significant differences in the expression of *RMB8A*, *PEX11B*, or *LIX1L* between the individuals with both the 1q21.1 deletion and rs61746197 G compared with those carrying one or the other ([Supplemental Fig. 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004564/-/DC1)).

![Schematic of 1q21.1 locus. The deleted region in family NCI-107 is shown in relation to the deletion previously reported in thrombocytopenia-absent radius (TAR) syndrome based on the hg38 reference genome. The transcription factor binding site (TFBS) affected by rs61746197 A \> G is denoted as are the locations of the previously TAR-associated SNPs, rs139428292 and rs201779890.](MCS004564Bro_F2){#MCS004564BROF2}

We hypothesized that the rs61746197 variant allele (G) could possibly alter TFBS and used TRANSFAC to query the region surrounding the SNP ([@MCS004564BROC13]). According to the TRANSFAC database, rs61746197 A \> G overlaps a putative RelA--p65 binding motif, a component of the NF-κB transcription factor complex ([Fig. 2](#MCS004564BROF2){ref-type="fig"}). We also examined the ENSMBL database to determine additional TFBSs overlapping with the SNP. TFBS motifs in Ensmbl with high information content under the SNP include PBX4::HOXA10, CUX1, SOX9, and others ([Table 4](#MCS004564BROTB4){ref-type="table"}). Given the known roles of several of these factors in hematological development ([@MCS004564BROC19]) and/or their importance in bone remodeling and development ([@MCS004564BROC23]), we proceeded to test whether the rs61746197 variant allele (G) disrupts transcription factor binding in vitro by EMSA.

###### 

Variant table

  Gene                                                                                       Chromosome   HGVS DNA reference                                HGVS protein reference   Variant type   Predicted effect (substitution, deletion, etc.)   dbSNP/dbVar ID   Genotype (heterozygous/homozygous)
  ------------------------------------------------------------------------------------------ ------------ ------------------------------------------------- ------------------------ -------------- ------------------------------------------------- ---------------- ------------------------------------
  *PEX11B*: 2KB upstream variant; *GNRHR*2: noncoding transcript variant; *RBM8A* (3′ UTR)   1            NC_000001.11:g.145919695T \> C GRCh38.p12 Chr 1   N/A                      SNV            Substitution                                      rs61746197       A \> G heterozygous
  Deletion; Chr 1: 145,601,946--148,597,425                                                  1            Chr 1:145,601,946--148,597,425 GRCh38.p12 Chr 1   N/A                      Deletion       Deletion                                          N/A              Heterozygous deletion

EMSA probes containing the rs61746197 reference (A) or the alternative allele (G) were incubated with nuclear extracts of K562 cells ([Fig. 3](#MCS004564BROF3){ref-type="fig"}A). Unstimulated K562 extract produced a bandshift on both the reference (A) and alternative (G) probe. This shift was competed away with equimolar quantities of cold reference (A) probe but required threefold excess cold alternative (G) probe to perturb the shift characteristics. These differences indicate that transcription factors bind to the reference allele (A) with a higher binding efficiency than the alternative (G) allele. Interestingly, stimulation of the K562 cells with TPA to induce the megakaryocyte differentiation pathway abrogated the observed shift of both the reference and alternative probes. Because RelA--p65 is a component of the NF-κB transcription factor complex, we evaluated whether the addition of anti-NF-κB--p65 antibody changed binding between the probe and nuclear factor(s). Addition of anti-NF-κB--p65 antibody disrupted the bandshift but did not result in a super-shift ([Fig. 3](#MCS004564BROF3){ref-type="fig"}B), indicating that RelA is likely binding to the locus, but the antibody blocks this interaction.

![Electromobility shift assays (EMSAs) suggest that rs61746197 A \> G is a functional SNP. (*A*) Ten micrograms of unstimulated nuclear extract from K562 cells was incubated with reference (Ref, R) or alternative (Alt, A) probe as indicated. Cold Ref probe titrates signal away from Alt at a lower stoichiometric ratio than the converse (arrow and compare lanes *11*--*13* with *6*--*8*). (*B*) Unstimulated extract (*left* panel, U) exhibits a markedly stronger baseline shift than TPA stimulated extract (*right* panel, S). Unstimulated nuclear extract (U) when incubated with labeled alternative probe (A) produces a novel secondary shift not observed with either the reference probe (R) or the TPA stimulated extract (S). Addition of RelA--p65 antibody abrogates this secondary shift (arrow).](MCS004564Bro_F3){#MCS004564BROF3}

DISCUSSION {#s3}
==========

Our data show that the 1q21.1 TAR-associated deletion in combination with the G variant of rs61746197 on the nondeleted chromosome results in a TAR-like phenotype notable for lack of thrombocytopenia but with other clinical features of TAR. This SNP appears to be associated with a milder hematologic presentation as the proband developed very mild thrombocytopenia at age 12 yr and thrombocytopenia has not occurred in his sister. The upper limb bony abnormalities in these siblings are consistent with other reported TAR cases ([@MCS004564BROC21]). About one-third of TAR cases have been noted to also have hypoplasia of the ulnae and/or humerus ([@MCS004564BROC9]). Similar to as noted in the sister, unilateral radial aplasia or hypoplasia has been reported in six literature cases ([@MCS004564BROC9]). Both siblings had other congenital anomalies sometimes reported in TAR, including heart and renal abnormalities.

To functionally characterize the potential role of rs61746197 A \> G in the clinical manifestations in these siblings, we first evaluated the expression of genes in the region near the SNP and in the deleted locus. However, we detected no differences in the expression of *RMB8A, PEX11B*, or *LIX1L* genes in cell lines derived from the siblings reported here or their parents. Notably, we also did not detect significant differences in *LIX1L, PEX11B*, and/or *RBM8A* expression for 5′ UTR rs139428292G \> A carriers with versus those without the 1q21.1 deletion. The 5′ UTR SNP (rs139428292G \> A) is a predicted expression quantitative trait locus (eQTL) in many tissues ([Supplemental Fig. 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004564/-/DC1)), and reports of TAR patients with this SNP and a 1q21.1 deletion suggest reduced *RBM8A* expression, in addition to classic TAR clinical phenotypes. In contrast, the intron 1TAR-associated SNP (rs201779890 G \> C) and this new 3′ UTR SNP (rs61746197 A \> G) are not predicted eQTLs in GTEx ([@MCS004564BROC6]), have similar minor allele frequencies ([Table 3](#MCS004564BROTB3){ref-type="table"}), and are reported in patients with physical manifestations of TAR but lacking the typical neonatal thrombocytopenia.

We hypothesized that the role of the regulatory element(s) containing rs61746197 A \> G is important in other tissue types, in specific stages of development, and/or in earlier stages of hematopoiesis. To further explore this hypothesis, we performed EMSAs and found that the shift observed on the alternative (G) allele could be disrupted by incubation with NF-κB--p65(RelA) antibody. NF-κB--p65(RelA) is one of the factors predicted to bind to the locus, and its core binding site lies over rs61746197 A \> G. We also observed that only unstimulated and not TPA-stimulated nuclear extracts of K562 cells contained sufficient levels of the factor that induce the mobility shift. Previous reports indicate that RelA translocates into the nucleus upon TPA treatment in HeLa cells, but not in K562 cell lines ([@MCS004564BROC8]). Taken together, these results suggest the G variant of rs61746197 A \> G could be a functional enhancer/repressor element in certain cell types and at particular stages of development.

In summary, the clinical phenotypes of these patients and EMSA data suggest an association between hemizygosity for rs61746197 A \> G and absent radius syndrome, a variant of thrombocytopenia-absent radius syndrome. The 1q21 chromosomal locus remains challenging to annotate and multiple sequencing approaches may be required to identify novel disease-associated variants. Additional studies are warranted to identify the specific factor(s) responsible and their timing in relation to hematopoiesis and development.

METHODS {#s4}
=======

Study Participants {#s4a}
------------------

Individuals with TAR and their families were participants in the IRB-approved longitudinal cohort study at the National Cancer Institute (NCI) entitled "Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes (IBMFS)" (ClinicalTrials.gov Identifier: NCT00027274, <https://marrowfailure.cancer.gov>) ([@MCS004564BROC3]). Participants completed comprehensive family and individual history questionnaires. Medical records were reviewed in detail, and biospecimens were collected. The individuals reported here, family NCI-107, also underwent comprehensive clinical evaluations by the IBMFS study team at the National Institutes of Health Clinical Center, Bethesda, MD. DNA was extracted from whole blood by standard methods.

Genomic Characterization {#s4b}
------------------------

The genomic characterization of family NCI-107 started in 2007 and proceeded over many years as methods for detecting variants in the 1q21.1 chromosomal region improved. Initially, array comparative genomic hybridization (aCGH) using Agilent 244K Human aCGH design 14693 and Agilent custom 4 × 44K designs 17773, 18388, and 19085 was performed on whole-blood DNA from the affected siblings and their parents (Agilent, Inc.). The presence of the 1q21.1 deletion in the siblings and one parent was confirmed in a CLIA-certified laboratory. A custom sequencing library was created with SureSelect probes (Agilent, Inc.) designed to target the deleted region (hg19 Chr 1:145341190-146164640) to evaluate the nondeleted region for novel variants.

The sequence alignment challenges at 1q21.1 led us to perform whole-exome sequencing (WES) on the siblings and their parents to assess coding regions for potential disease-associated variants as previously described ([@MCS004564BROC4]). Synonymous and low-quality variants were removed, and the remaining variants were filtered to identify variants shared between the siblings. We first focused on variants at 1q21.1 that were homozygous in the children and present in the parent without the 1q21.1 deletion. We filtered variants in the exome using autosomal recessive inheritance models.

Whole-genome sequencing was also performed on NCI-107-2 in a pilot study utilizing 10× Genomics Gemcode technology initially aimed at testing the ability of this platform to detect heterozygous deletions. The WGS alignments were conducted on hg38.

We used the liftover tool in the UCSC Genome Browser to map all coordinates to hg38 ([Table 2](#MCS004564BROTB2){ref-type="table"}). TRANSFAC was used to identify putative TFBS at or around the SNP of interest, rs61746197 (QIAGEN) ([@MCS004564BROC13]).

Functional Studies of rs61746197 A \> G {#s4c}
---------------------------------------

Changes in expression of *RBM8A* (Hs04234933_g1), *PEX11B* (Hs00948294_m1), and *LIXL1*(Hs00542268_m1) were evaluated by qPCR using RNA isolated from EBV-immortalized lymphoblasts and/or fibroblast cells from all four family members. EBV-lymphoblasts were cultured at 5%O~2~, 5%CO~2~, 2 psi in an AVATAR incubator system (Xcell Biosciences) in RPMI supplemented with 10% FBS. Cells were harvested at \>70% viability; ∼5 × 10^6^ cells were harvested for RNA extraction. Fibroblast RNA was extracted directly from cryopreserved primary cell cultures. RNA was extracted using RNAeasy plus mini kit (QIAGEN), and 50 ng of total RNA was reverse transcribed using Superscript III first-strand synthesis kit primed with random hexamers (Thermo Fisher). Changes in target levels were quantified using TaqMan probes (Thermo Fisher) by the ΔΔCT method after normalization to GAPDH (Hs99999905_m1) using a minimum of three technical replicates.

EMSAs were performed using TPA-stimulated and unstimulated nuclear extracts of K562 cells (Active Motif). Ten micrograms of the nuclear extracts were incubated on ice for 30 min with 3.3 nM of IR700 labeled probes ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004564/-/DC1)) (Integrated DNA Technologies), poly-dIdC, glycerol binding buffer, and increasing molar equivalents of unlabeled competitor probe as indicated (where 1× = 3.3 nM, 2× = 6.7 nM, 3× = 10 nM, final concentration of unlabeled competitor probe). In some reactions, anti-NF-κB--p65 subunit antibody (MAB3026, Millipore Sigma) or volumetric equivalent of glycerol was added after the initial 30 min and incubated for an additional 15 min at room temperature. Reactions were halted with the addition of 5× loading dye and loaded quickly on 7.5% Criterion gels (Bio-Rad). The gels were run for 50 min at 150 V and imaged on a Chemidoc MP system (Bio-Rad).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Genomic data are available through controlled access in dbGaP per the National Institutes of Health (NIH) genomic data sharing policy (Study Accession: phs001481.v1.p1). The variants were submitted to ClinVar (<https://www.ncbi.nih.nlm.gov/clinvar/>) and can be found under accession numbers SCV000995057 and SCV000995062.1.
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